Legend Biotech's novel in vivo CAR-T therapy shows 100% response rate in early blood cancer trial
LEGN sits 57% above its 52-week low of $16.24.
Summary
Legend Biotech reported strong preliminary Phase 1 data for its novel in vivo CAR-T therapy, LB2501, for blood cancer. In the higher-dose cohort, all six patients with relapsed/refractory B-cell non-Hodgkin lymphoma responded, with five achieving a complete response. This therapy is designed to generate CAR-T cells directly within the patient, potentially simplifying treatment and expanding access. This positive pipeline development follows recent strong sales for their approved CARVYKTI product and early positive data for another experimental therapy. Further data is expected at a medical meeting later this month.
At the time of this announcement, LEGN was trading at $25.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $45.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.